Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Pipeline Update

Arcus Biosciences, Inc. reported its financial results for the third quarter ended September 30, 2025, and provided updates on its clinical-stage investigational molecules and discovery programs. The company highlighted the performance of casdatifan, a HIF-2a inhibitor, which demonstrated a median progression-free survival (mPFS) of 12.2 months in late-line kidney cancer. Multiple readouts from the ARC-20 study of casdatifan are expected in 2026. Additionally, domvanalimab plus zimberelimab and chemotherapy showed a median overall survival (OS) of 26.7 months in the Phase 2 EDGE-Gastric study. Arcus also unveiled its portfolio of five programs targeting inflammatory and autoimmune diseases, with a small molecule targeting MRGPRX2 expected to enter the clinic in 2026. The company reported $841 million in cash, cash equivalents, and marketable securities at quarter end, providing a cash runway through the PEAK-1 Phase 3 readout.